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Effects of the tailored activity program
(TAP) on dementia-related symptoms,
health events and caregiver wellbeing: a
randomized controlled trial
Laura N. Gitlin1,2,3*, Katherine Marx2, Catherine Verrier Piersol4, Nancy A. Hodgson5, Jin Huang2, David L. Roth2 and
Constantine Lyketsos2

Abstract
Background: People living with dementia (PLWD) and caregivers are adversely impacted by lack of meaningful
activity leading to worse symptoms and impaired quality-of-life. There is a critical need to develop effective and
well-tolerated treatments that mitigate clinical symptoms, engage PLWD and support caregiver wellbeing. We
tested whether, compared to attention control, the Tailored Activity Program (TAP) reduced clinical symptoms and
health-related events, and improved caregiver wellbeing, and if TAP activities were well-tolerated.
Methods: We conducted a single-blind randomized controlled trial among 250 dyads recruited from BaltimoreWashington DC (2012–2016) with a dementia diagnosis and clinically significant agitation/aggression. Dyads were
randomized to TAP (n = 124) or attention control (n = 126), and interviewed at baseline, 3 (endpoint) and 6-months
(follow-up) by interviewers masked to group allocation. TAP assessed PLWD abilities/interests, instructed caregivers
in using prescribed activities, and provided dementia education and stress reduction techniques. Attention controls
received disease education and home safety tips. Both groups had up to 8 home visits over 3-months. The primary
outcome was frequency by severity scores for agitation/aggression subscales of Neuropsychiatric Inventory-Clinician
using caregiver ratings. Secondary outcomes included number of instrumental (IADL) and activities of daily living
(ADL) needing assistance, caregiver wellbeing, and confidence using activities. Health-related events (PLWD death,
hospitalizations, caregiver hospitalization, depression) and perceived study benefits were captured over 6 months.
PLWD tolerability of prescribed activities was examined.
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Results: Of 250 dyads, most caregivers were female (81.2 %, n = 203), non-spouses (54.4 %, n = 136), white (59.2 %,
n = 145) or African American (36.7 %, n = 90) with mean age = 65.4 (SD = 12.6). PLWD were mostly female (63.2 %,
n = 158) with mean age = 81.4 (SD = 7.9), and mean MMSE = 14.3 (SD = 7.8). At 3-months, compared to controls,
TAP conferred no benefit to agitation/aggression (p = 0.43, d = 0.11), but resulted in less IADL (p = 0.02, d=-0.33), and
ADL (p = 0.04, d=-0.30) assistance, improved caregiver wellbeing (p = 0.01, d = 0.39), and confidence using activities
(p = 0.02, d = 0.32). By 6-months, 15 PLWD in TAP had ≥ 1 health-related event versus 28 PLWD in control,
demonstrating 48.8 % improvement in TAP (p = 0.03). TAP caregivers were more likely to perceive study benefits.
Prescribed activities were well-tolerated.
Conclusions: Although TAP did not benefit agitation/aggression, it impacted important outcomes that matter to
families warranting its use in dementia care.
Clinical trial registration: Clinicaltrials.gov # NCT01892579 at https://clinicaltrials.gov/; Date of clinical trial
registration: 04/07/2013; Date first dyad enrolled: 15/11/2013.
Keywords: Behavioral symptoms, Family caregiving, Tailored activities, Quality of life, Nonpharmacological strategies

Introduction
Dementia is a worldwide public health challenge affecting over 50 million individuals and their families with
this number expected to triple by 2050 [1]. The effect of
dementia is profound impacting behavioral patterns,
daily functioning, quality of life, activity engagement and
health care utilization [2, 3]. Caregivers experience daily
care challenges resulting in increased risk for depression,
and poor quality of life [4]. A major cause of adverse
outcomes for people living with dementia (PLWD) and
caregivers are neuropsychiatric symptoms (NPS) which
are almost universal and occur across all disease stages
and etiologies [5]. Pharmacological options for NPS have
modest benefits, while some are associated with significant risks including mortality, and do not typically address the many care challenges families identify as most
problematic to them [6, 7]. Moreover, in the absence of
effective pharmacotherapies that slow disease progression, there is an urgent need to develop and test the effectiveness of well-tolerated treatments that improve
NPS and thereby enhance quality of life of PLWD and
their caregivers [4].
Nonpharmacological approaches have been identified
as first line treatments and have potential to address
NPS as well as associated functional dependence, and
caregiver distress [8, 9]. Although various nonpharmacological strategies have been tested, efficacy studies vary
in quality, and results are inconsistent [10–12]. Moreover, most nonpharmacological approaches involve rapport building and individualized attention, yet few
studies control for potential effects of attention on outcomes [13] .
An emerging evidence base suggests that activity engagement can help PLWD by reducing one of the most
serious forms of NPS, agitation/aggression [11, 12, 14,
15]. Agitation/aggression-type behaviors can occur at
any stage of the disease or with any etiology, but are

particularly acute at the moderate stage when more
hands-on care by family members are typically required.
Lack of meaningful activity is also an expressed unmet
need among PLWD and caregivers [16–18]. In previous
trials, we showed that the Tailored Activity Program
(TAP), which tailors activities to abilities and interests
and instructs caregivers in their use in addition to providing disease education and stress reduction techniques,
resulted in fewer NPS, reduced functional dependence,
and enhanced caregiver wellbeing [15, 19–22]. However,
it is unclear from these previous trials whether personalized attention contributes to or accounts for positive
NPS and other favorable outcomes [14, 15]. Also unclear
is whether disease education and support alone would
reduce agitation/aggression.
The objective of this phase III randomized clinical trial
was to test the effectiveness of TAP to reduce agitated
and aggressive behaviors, two of the most prevalent and
upsetting behavioral symptoms of dementia [23] for
caregivers and PLWD. We hypothesized that participation in TAP compared to an attention control would result in a reduction in agitated/aggressive behaviors at
three months. We also sought to determine if TAP impacted other outcomes that matter to PLWD and caregivers including functional dependence, health-related
events, and caregiver wellbeing and confidence using activity as a care strategy. We hypothesized that PLWD in
comparison to those in attention control would experience less functional dependence at three months, and
fewer health-related events (death, hospitalizations,
emergency room visits, and depression and/or suicidal
ideation as reported by their caregivers) by six months.
Similarly, we hypothesized that caregivers in TAP compared to attention control would report better overall
well-being and confidence using activities as part of daily
care at three months, and fewer health-related events
(hospitalizations, elevated depression scores) by six
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months. We also compared caregiver perceived study
benefits at six months with the expectation that TAP
caregivers would more likely report benefits than attention control caregivers. Finally, we evaluated whether activities prescribed in TAP were tolerated by PLWD
when used by caregivers during the three-month intervention period.

Methods
We report on a single blind two-armed randomized trial
conducted between 2012 and 2016 in the Baltimore and
Washington, DC regions. The trial was monitored by a
data and safety monitoring board and overseen by a
Johns Hopkins University Institutional Review Board.
Written informed consent was obtained from caregivers
and PLWD, or proxy if the PLWD was unable to consent [24]. Details of the study protocol have been described elsewhere [25]. All participants were assessed in
their homes at baseline, 3 months (main study endpoint), and 6-months by trained research assistants
masked to group allocation. All intervention sessions
also occurred in homes. The trial adhered to CONSORT
guidelines.
Study population

Participants were recruited from the Baltimore region
using various strategies including mailings to families by
service providers, media announcements, talks at local
community health seminars and events, and online trial
searches (e.g., Alzheimer’s Association TrialMatch® and
www.clinicaltrials.gov).
Eligibility criteria extended to both caregivers and
PLWD. Dyads were eligible if the PLWD was Englishspeaking, had a physician’s diagnosis of dementia (mild,
moderate, severe); was able to participate in at least two
activities of daily living; and had agitated/aggressive-type
behaviors. For the latter, caregivers had to endorse at
least one behavior listed on the agitation and/or aggression domain of the Neuropsychiatric Inventory (NPI-C)
with a frequency or severity score of ≥ 2 (moderate) [26].
If only one item on the agitation/aggression subscales
was endorsed with a frequency < 2, then at least two
other behaviors on the NPI-C had to be endorsed with a
frequency or severity score ≥ 2. Eligibility was confirmed
after review by a medical team (two Gero-psychiatrists
and a nurse PhD gerontologist) to assure a sample with
clinically meaningful neuropsychiatric symptoms. Additionally, as per best practice in clinical trials, if PLWD
were on any of four classes of psychotropic medications
(antidepressants, benzodiazepines, antipsychotics, or anticonvulsants) or an anti-dementia medication (memantine or cholinesterase inhibitor), a stable dose for 60
days was required prior to enrollment to minimize confounding effects of medications on outcomes.
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Dyads were eligible if the caregiver was Englishspeaking; a family member (relative, neighbors, fictive
kin), ≥ 21 years of age; lived with PLWD, or within 5
miles or 15 min driving time; accessible by telephone to
schedule interview and intervention sessions; and
planned to live in area for at least 6 months. As per best
practice in clinical trials, caregivers taking a psychotropic
medication (antidepressants, benzodiazepines, antipsychotics, or anticonvulsants), had to have been on a stable
dose for 60 days prior to enrollment.
Dyads were excluded if PLWD had a previous psychiatric history (schizophrenia, bipolar disorder), dementia
secondary to head trauma if unresponsive to their environment (e.g., unable to understand short commands or
recognize a person coming in or out of the room) or if
the caregiver was concurrently enrolled in another clinical trial or planned to place PLWD in a residential facility within 6 months. Finally, dyads were excluded if
either had a terminal illness with life expectancy < 6
months, were in active cancer treatment, or had > 3
acute medical hospitalizations in the past year. Criteria
were designed to minimize attrition due to poor health
or exclude dyads who would not potentially benefit from
study participation.
Screening processes have been reported in detail elsewhere [25] and enrollment and retention results are presented in Fig. 1. Interested caregivers were initially
screened by telephone with those preliminarily eligible
having an in-home visit to obtain informed consent and
conduct the baseline interview. (Figure 1) Following
baseline interview, its review by the medical team and
their final determination of eligibility, randomization
occurred.

Randomization

Participants were randomized 1:1 to TAP or an attention
control group using a computer-based assignment
scheme stratified by cognitive status using the MiniMental Status Examination (MMSE > 10 vs. MMSE ≤ 10)
in randomized block sizes. Allocation concealment was
protected by altering block sizes for stratification and
using double opaque envelopes prepared by the statistician which were opened only by the project manager following completion of a baseline interview.
Interventions

The Tailored Activity Program (TAP) has been described in detail elsewhere [25, 27, 28] Briefly, the program is delivered by occupational therapists (OT) and
unfolds in three phases involving up to 8, 1 to 1½ hour
sessions over three months. The first phase (up to two
sessions), involves assessment of PLWD preserved abilities, functional challenges (fall risk, executive function,
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sensory impairments) and interests (roles, occupations,
routines, activities), caregiver communication style,
availability and readiness to use activities, and the physical environment (lighting, seating, noise, clutter). The
assessment phase includes participation of caregivers
and PLWD and yields an understanding of preserved
abilities including areas of executive dysfunction from
which strategies for engaging the PLWD in activities of
intrinsic interest are formulated.
Based on assessments, the second phase, implementation, involves up to four sessions in which the OT identifies three specific activities of interest with each then
tailored to PLWD functional, caregiver and environmental profiles. Caregivers are then instructed in their use
including how to set-up an activity, communicate effectively, provide verbal or physical cues and/or supervise.
Additionally, environmental adjustments (decluttering,
seating, lighting) are implemented to support engagement in prescribed activities. To learn activity use, caregivers initially observe OTs providing each activity to
PLWD while explaining the process and eliciting PLWD
input. Then, caregivers try engaging PLWD in that activity as OTs observe, prompt and support the dyad. Caregivers are then asked to try the activity before the
following session. Caregivers learn through observation
and then through doing, and strategies are also provided
in the form of written instructions, referred to as the
TAP Activity Prescription for each prescribed activity. In
each subsequent session, the activity previously introduced is reviewed and then a new activity prescription
offered and practiced.
The third phase, generalization, involves up to two sessions with caregivers alone. In these sessions, OTs help
caregivers generalize strategies from those learned for
using activities to care challenges such as helping with
bathing or dressing. For example, cueing techniques for
supporting activity engagement may be able to assist
PLWD in self-care. Simplifying the physical environment
to support activity engagement can also be applied to
everyday tasks such as bathing or grooming. Throughout
TAP sessions, caregivers receive dementia education
(e.g., behavioral symptoms are not intentional), and
practice strategies and stress reduction techniques.
TAP is person-centered such that activities are designed based on interests and abilities of PLWD. As activities match interests, use familiar objects and are
graded to functional profiles, activities provided differ
vastly. Any one activity can be modified to fit the person’s cognitive functional abilities. For example, a PLWD
with high cognitive status who enjoys gardening, may be
able to engage in multiple steps such as digging a hole
and planting flowers in their back yard (if not a fall risk).
A PLWD with low cognitive status who previously
enjoyed gardening, may be able to engage in a single
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step such as placing plastic flowers in a vase that is
placed in their visual field.
In TAP, an activity can be designed for PLWD with
MMSE scores ranging from 0 on up.
Examples of activities that were provided in this trial
for those with low cognitive scores on the MMSE,
sensory-type activities (music, balloon toss, watching nature/animal videos, using an activity board with objects
of intrinsic interest, chair exercises); for those with moderate range scores, repetitive type activities (vacuuming,
sorting coins or other objects, washing dishes, folding
laundry, mixing salad ingredients); and for those with
high cognitive status, multi-step activities (preparing a
sandwich or salad; multi piece jigsaw puzzles, setting the
table, dancing, walking, gardening).
OTs were trained through readings, a treatment manual, didactic and interactive teaching modalities, and bimonthly supervision meetings. To monitor fidelity, all
TAP visits were audiotaped of which 10 % were randomly selected for formal evaluation by staff who rated
tapes using a score sheet with a priori criteria followed
by feedback to the OT. At the conclusion of each session, OTs recorded the date and start and stop time for
each session, if caregivers used activities between sessions and if so frequency of their use, and caregivers perceptions as to the level of PLWD engagement during the
prescribed activity.
The attention control group, described in detail elsewhere [25], was designed to match TAP’s therapeutic
engagement with caregivers. Delivered by trained research staff over 8 home sessions of up to 1 to 1½ hours
each, caregivers received disease education, and home
safety assessment and tips. However, sessions did not involve a systematic assessment of PLWD nor did caregivers receive education about NPS, functional decline,
or an understanding of the abilities of PLWD or tailored
activities, and stress reduction techniques, the active ingredients of TAP.
Measures

Demographic characteristics included age in years, sex
(male, female), race (white, African American, Latino,
Asian, Native American, other), education (≥ high
school, some college/associates, college degree/postgraduate degree), marital status (married/living as married, not married) and relationship to PLWD (spouse,
non-spouse).
The primary trial outcome was frequency by severity
scores of agitation/aggression behaviors at 3 months as
measured by two domains of the Neuropsychiatric
Inventory-Clinician version (NPI-C) [26]. For each of
the 13 agitation subscale items, caregivers rated frequency (0 = never to 4 = very frequently). If frequency
was greater than 0, then caregivers rated the severity
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(1 = mild to 4 = major source of distress). When frequency was 0, severity was set to 0. The 13-item agitation subscale had frequency and severity scores ranging
from 0 to 52. For each of the 8-item aggression subscale items, caregivers similarly rated frequency and severity (range from 0 to 32). The primary outcome measure was obtained by multiplying the frequency rating
times the severity rating for each item and adding these
products across all 21 items on the two subscales with
total scores potentially ranging from 0 to 336 (highest
observed maximum score for this sample was 224), and
higher scores reflecting greater frequency by severity.
Secondary outcomes included functional dependence,
caregiver wellbeing and confidence using activities, and
health-related events for PLWD and caregivers. The
PLWD functional dependence in instrumental (IADL)
and activities of daily living (ADL) was measured using
the Caregiver Assessment of Function and Upset
(CAFU) [29]. Caregivers rated eight IADLs (telephone,
shopping, meal preparation, housework, laundry, travel,
medicine, and finances), and seven ADLs (bathing,
dressing upper body, dressing lower body, toileting,
grooming, eating, getting in/out of bed) based on yes
(1) PLWD needs assistance (supervision or hands-on) or
no (0), PLWD did not need assistance. Totals for each
area (ADL & IADL) were calculated with higher scores
indicating more activities for which assistance was
needed.
Caregiver well-being was measured with the 13-item
Perceived Change for Better Index (α = 0.86), which assesses affective wellbeing, somatic, and ability to manage
day-to-day care) along a five-point scale (1 = gotten a lot
worse to 5 = improved). A total score was calculated by
summing all 13 items, with higher scores indicating
positive change [30].
Caregiver confidence using activities was measured
with five items [14], from not at all confident (0) to very
confident (10). Items included level of confidence: identifying daily or recreational activities PLWD is capable of
doing; involving PLWD in daily and/or recreational activities; using activities to distract PLWD; using meaningful or pleasant activities to manage boredom, upset
or agitation in PLWD; and setting up an activity (e.g.
dressing, bathing, recreational activity) for PLWD. Items
were summed (range 0–50) and an average score over
the five items derived. Higher scores indicate greater
caregiver confidence using activities with PLWD.
Number and type of health-related events were captured over 6-months by interviewers and interventionists. For PLWD, four events were followed: death,
hospitalization, emergency room visits, and depression
and/or suicidal ideation as reported by their caregivers.
For caregivers, two events were followed: hospitalization
and elevated depression scores (PHQ-9 ≥ 15) and/or
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suicidal ideation [31]. Depression was captured using the
PHQ-9, a brief, psychometrically sound 9-item selfreport measure which aligns with DSM diagnostic categories. To examine group differences at baseline, a
mean total severity score was calculated by summing responses across the nine items which were rated as occurring not at all (0), several days (1), more than half the
days (2), nearly every day (3). For this study, we were interested in examining the percentage of caregivers with
scores ≥ 15, indicative of major depression to evaluate
group differences over 6 months in this subgroup of
caregivers with significant symptomatology.
We also evaluated whether caregivers perceived any
study benefits using a brief telephone survey at six
months. The survey consisted of 9 questions adapted
from prior trials [32]: Was study clearly explained? Were
you and your relative treated with respect? How much
did you benefit from participation? How much did participation help you better understand dementia? How
much did participation help you feel more confident
dealing with behavioral symptoms? How much did participation make your life easier? How much did participation help enhance your ability to care for your
relative? How much did participation in the project help
improve your relative’s life? And How much did participation help to keep your relative living at home? Each
question was answered by one of three responses: not at
all, some, or a great deal. For two additional questions,
“did project require too much work/effort,” and “would
you recommend this project to others,” caregivers
responded either yes or no. We anticipated that both
treatment groups would respond favorably regarding
their experiences in the study, but that caregivers in the
TAP group would indicate greater perceived benefit.
Finally, to evaluate whether prescribed TAP activities
were tolerated by PLWD, caregivers were asked by interventionists at each intervention session if they had used
a prescribed activity between sessions; and if yes,
whether they observed (not at all, somewhat or very
much) three emotional states (interest or pleasure, anxiety or upset, agitation or disruptive behaviors) in the
PLWD during the activity.
Statistical analysis

Based on a pilot study, we assumed 20 % attrition and
80 % power to detect a moderate effect size at 3 months
[27]. We set alpha to equal 0.05. Given those numbers,
we planned to randomize 250 to TAP or attention
controls.
First, chi-squared and t-test tests were used to compare TAP and control dyads on baseline characteristics.
Next, an intention-to-treat analysis was performed. For
the primary outcome, a sensitivity analysis was conducted using multiple imputation for 44 cases with
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missing data at the 3-month assessment. Results from
the imputation analysis were not substantively different
from the complete case analyses, so only the complete
case findings are further reported here. For these analyses, all randomized dyads who had 3-month follow-up
data were analyzed in the groups to which they were
assigned regardless of exposure level to treatment. For
main treatment effects, we constructed general linear
models to compare each outcome at 3-months between
TAP and attention control groups. Baseline value of the
outcome measure and baseline MMSE were included as
covariates. Also, caregiver sex, race, education, and relationship with PLWD were identified a priori to be included in the analytic models as covariates given their
known relationship to the primary and secondary outcomes. Standardized effect sizes (d) were calculated by
dividing the differences in covariate-adjusted means by
the square root of the mean square error from the
model [33].
TAP and control groups were compared on incidence
of each type of health event occurring over 6 months
using chi-squared tests. The total number of health
events experienced by PLWD and caregiver was counted
and compared between TAP and control groups with
Poisson regression model adjusting for the same covariates as in the main treatment effect models.
To evaluate perceived study benefit, an unadjusted logistic regression was used to evaluate whether TAP caregivers had higher odds of perceiving benefit from the
study compared to attention control caregivers. To
examine PLWD tolerability of prescribed activities, frequencies and percentages of responses to three emotional states were computed.
Statistical analysis was performed with SAS, version
9.4 (SAS Institute, Cary, NC). All analyses were conducted with the significance level set at p < 0.05 and
were 2-sided.

Results
Of 765 inquiries (Figs. 1), 603 (78.8 %) caregivers were
screened by telephone of whom 345 (57.2 %) were determined to be eligible. Of these, 69 (20.0 %) were eligible
but unwilling to participate and 16 (4.6 %) were found
ineligible between the initial screen and the baseline
interview appointment. A total of 266 (77.1 %) of the
345 were interviewed at home of whom 250 (72.5 %)
were confirmed as eligible and interested in study participation resulting in 124 dyads randomized to receive
TAP and 126 randomized to receive the attention control. Forty-four (17.6 %) of the randomized dyads did not
complete the three-month follow-up assessment and 74
(29.6 %) did not complete a six-month follow-up. A total
of 79 (63.7 %) caregivers in TAP and 61 (48.4 %) caregivers in control were available for the brief six-month
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follow-up telephone survey to obtain caregiver satisfaction with study participation and perceived benefit.
For dyads lost to follow-up by 3 months, caregivers reported lower cognitive status and poorer quality of life
for the PLWD, and a poorer relationship (p < 0.05) at
baseline compared to retained dyads.
Among randomized dyads, most caregivers were female (n = 203, 81.2 %), Caucasian (n = 145, 59.2 %) or African American (36.7 %, n = 90), with an average age of
65.20 years (SD = 12.64, range = 28–93). Caregivers were
mostly adult daughters (n = 109, 43.6 %) or wives (n = 79,
31.6 %), followed by husbands (n = 35, 14.0 %). PLWD
were mostly female (n = 158, 63.2 %) and Caucasian (n =
149, 59.6 %) with an average age of 81.52 years (SD =
8.00, range = 56–99). Descriptive baseline information
for the 250 dyads who were randomized are presented
in Table 1. (Table 1)
Caregivers reported low depressive symptomatology.
At baseline, both groups had a mean score of 5.7 (p =
0.99) indicative of mild depressive symptoms, with only
0.05 % in TAP and 0.04 % in the attention control group
having scores ≥ 15 (indicative of moderate to severe clinical depression). At three-months, scores remained relatively stable at three months and the percent of
caregivers with moderate to severe clinical depression
scores did not meaningfully vary between the groups.
Treatment dose

Of 124 dyads assigned to TAP, 5 (4.0 %), dyads did not
participate in any sessions and 119 (96.0 %) had at least
one session. Of those, 111 (93.3 %) completed ≥ 4 sessions, considered the minimal treatment threshold with
8 (6.7 %) dyads receiving ≤ 3 sessions. TAP dyads received a mean (SD) of 6.9 (2.1) home sessions with an
average of 78.5 (23.0) minutes per session. Of 126 dyads
assigned to the control group, 102 (81.0 %) participated
in at least one session. Of those, 90 (88.2 %) completed ≥
4 sessions with 12 (11.8 %) receiving ≤ 3 sessions. Control group dyads received a mean (SD) of 6.5 (2.5) sessions with an average of 54.4 (20.5) minutes per session.
Although TAP and control group participants had a
similar number of completed sessions (p = 0.18), the
average length of sessions was shorter by close to
24 min (p < 0.0001) for control group versus TAP dyads.
Tolerability of prescribed activities

Caregivers reported using the three prescribed activities
an average of 9.08 (SD = 8.47) times on their own between sessions in which prescribed activities were introduced, representing an average use of three times each
per the three prescribed activities in keeping with OT
recommendations. Caregivers also reported that when
using prescribed activities, 93.0 % of PLWD showed
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Table 1 Characteristics of People Living with Dementia and Their Caregivers by Treatment Arm and Total
Characteristic

Control Group (n = 126)

Intervention group (n = 124)

Total
(n = 250)

80.81 (8.25)

82.02 (7.55)

81.41 (7.92)

Χ2

t

p-value

1.21

0.23

People Living with dementia
Age, mean (SD), y
Sex, n (%)
Male

48 (38.10)

44 (35.48)

92 (36.80)

Female

78 (61.90)

80 (64.52)

158 (63.20)

79 (63.71)

70 (56.91)

149 (60.32)

Race, n (%)
White
African American

42 (33.87)

49 (39.84)

91 (36.84)

Other

3 (2.42)

4 (3.25)

7 (2.83)

25 (20.00)

21 (16.94)

115 (46.18)

Education, n (%)
≤High school
Some college

45 (36.00)

41 (33.06)

44 (17.67)

≥College

55 (44.00)

62 (50.00)

90 (36.14)

Married or living as married

68 (53.97)

64 (51.61)

132 (52.80)

Other

58 (46.03)

60 (48.39)

118 (47.20)

0.18

0.67

1.22

0.54

0.95

0.62

0.14

0.71

0.05

0.82

Marital status, n (%)

Living arrangement, n (%)
Alone

18 (14.29)

19 (15.32)

37 (14.80)

With caregiver

108 (85.71)

105 (84.68)

213 (85.20)

# of behavioral symptoms, mean (SD)

7.87 (2.52)

7.76 (2.29)

7.82 (2.40)

-0.36

0.72

MMSE score, mean (SD)

14.75 (7.49)

13.93 (8.16)

14.34 (7.82)

-0.83

0.41

65.44 (12.79)

65.29 (12.54)

65.37 (12.64)

-0.10

0.92

Male

20 (15.87)

27 (21.77)

47 (18.80)

Female

106 (84.13)

97 (78.23)

203 (81.20)

Caregivers
Age, mean (SD), y
Sex, n (%)

Race, n (%)
White

76 (61.79)

69 (56.56)

145 (59.18)

African American

42 (34.15)

48 (39.34)

90 (36.73)

Other

5 (4.07)

5 (4.10)

10 (4.08)

Education, n (%)
≤High school

58 (46.03)

57 (46.34)

46 (18.47)

Some college

24 (19.05)

20 (16.26)

86 (34.54)

≥College

44 (34.92)

46 (37.40)

117 (46.99)

1.43

0.23

0.73

0.69

0.38

0.83

0.53

0.47

0.42

0.52

Marital status, n (%)
Married or living as married

89 (71.20)

83 (66.94)

172 (69.08)

Other

36 (28.80)

41 (33.06)

77 (30.92)

Spouse

60 (47.62)

54 (43.55)

114 (45.60)

Non-spouse

66 (52.38)

70 (56.45)

136 (54.40)

Time of caregiving, mean (SD), y

3.87 (2.81)

3.94 (3.38)

3.90 (3.10)

Relationship to patient, n (%)

Abbreviation: MMSE Mini-Mental State Examination

0.17

0.86
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interest/pleasure somewhat or very much and most had
no signs of anxiety (73.6 %) or agitation (88.6 %). Conversely, 7.7 % reported observing that PLWD showed no
interest/pleasure, 5.5 % reported presence of anxiety/
upset and 3.4 % indicated some form of agitation/disruptive behavior when using the prescribed activities.
(Figure 2)

Outcomes

In unadjusted and adjusted analyses, no statistically significant differences were found from baseline to three
months on the primary study outcome variable of frequency by severity of agitation/aggression subscales.
For secondary outcomes, less assistance was needed
for TAP PLWD for both IADLs (adjusted mean difference =-0.33; 95 % confidence interval [CI] = (-0.62,
-0.05), p = 0.02, Cohen’s d = -0.33) and ADLs (adjusted
mean difference = -0.59; 95 % CI = (-1.15, -0.03), p =
0.04, Cohen’s d =-0.30) compared to attention controls
in unadjusted and adjusted analyses. Also, TAP caregivers reported greater confidence using activities (adjusted mean difference = 3.46; 95 % CI = (0.42, 6.50), p =
0.03, Cohen’s d = 0.32) and wellbeing (adjusted mean difference = 3.50; 95 % CI = (0.94, 6.06), p = 0.01, Cohen’s
d = 0.39) compared to attention control caregivers
(Table 2).

Health-related events

The unadjusted and adjusted Poisson models (not
shown) for the total number of health-related events for
PLWD and caregivers combined showed that TAP did
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not statistically significantly reduce these events, although non-significant reductions were observed in TAP
that ranged from 18 to 26 % by six months.
More detailed analyses of event types revealed that
there were a total of 115 health-related events (PLWD
death, hospitalizations, emergency room visits, depression/suicidal ideation; caregiver hospitalizations, depression/suicidal ideation) across both treatment arms. Of
the 115 health-related events, 65 (56.5 %) were associated with the PLWD (n = 11 deaths; 42 hospitalizations,
10 emergency room visit, and 2 reported depression/suicidal ideation), and 50 (43.5 %) were related to the caregiver (15 hospitalizations, 35 elevated depression scores
or suicidal ideation).
As to group differences, there were more PLWD
health-related events in the attention control (n = 43
events) versus in TAP (n = 22 events) for every category
(death, hospitalization, depression/suicidal ideation) except emergency room visits in which an equal number
of events were reported for both groups. Overall, this
represented a 48.8 % improvement in the number of
health-related events in TAP for PLWD.
With regard to the number of PLWD with one or
more health-related events, there was a statistically significant difference such that 15 PLWD in TAP versus 28
PLWD in attention control) had one or more healthrelated events (unadjusted p = 0.04; adjusted p = 0.03).
While there were 4 PLWD deaths in TAP versus 7 in attention control, this difference was not statistically significant (unadjusted p = 0.37; adjusted p = 0.38).
As to caregiver events, there were more hospitalizations in the attention control (n = 11 events) versus in
TAP (n = 4 events), representing a 63.6 % improvement

Fig. 2 Percent PLWD showing interest, anxiety or agitation with prescribed activities (n = 98)
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Table 2 Comparison of Intervention (n = 108) and Control (n = 98) Group at 3 Months
Variable

Baseline, mean (SD)

3-month follow-up,
mean (SD)

Adjusted Mean pd
Difference
value
Between
Groups (95 %
CI)

Control
Group

Intervention
Group

Control
Group

Intervention
Group

Agitation/aggression frequency X
severity

46.07 (40.27)

45.77 (40.96)

41.04 (40.92)

43.13 (43.32)

3.14 (-4.71,
10.99)

0.43

0.11

IADL dependence

6.96 (1.46)

6.81 (1.56)

7.50 (0.92)

7.16 (1.40)

-0.33 (-0.62,
-0.05)

0.02

-0.33

ADL dependence

3.67 (2.75)

3.58 (2.67)

4.49 (2.65)

3.88 (2.74)

-0.59 (-1.15,
-0.03)

0.04

-0.30

Confidence using activities

32.80 (11.96)

31.81 (11.85)

34.13 (11.30)

37.18 (12.35)

3.46 (0.42, 6.50)

0.03

0.32

Perceived wellbeing

34.27 (6.71)

35.27 (7.05)

38.26 (8.38)

41.73 (9.37)

3.50 (0.94, 6.06)

0.01

0.39

People Living with Dementia
Outcomes

Caregiver Outcomes

Note: Bold signifies significant p values. Abbreviations: ADL activities of daily living, CI confidence interval, IADL instrumental activities of daily living, SD standard
deviation. d = adjusted difference (intervention – control) in means divided by the square root of the mean square error. All analyses adjusted for baseline value
of dependent variable, caregiver sex, race, education, caregiver and patient relationship, and MMSE

in such events in TAP for caregivers. However, there
were slightly more elevated depression/suicidal ideation
events in TAP (n = 19 events) than in attention control
(n = 16 events).
As to the number of caregivers, there was a trend towards statistical significance with 3 caregivers in TAP
versus 10 in attention control for hospitalizations (unadjusted p = 0.06; adjusted p = 0.07).
However, for depression/suicidal ideation, slightly
more TAP caregivers (n = 16) versus control caregivers
(n = 14) scored ≥ 15 on the PHQ-9 (indicative of moderate clinical depression) or endorsed suicidal ideation
(unadjusted p = 0.66; adjusted p = 0.78). (Table 3).

Perceived benefits

TAP and control group caregivers similarly reported better dementia understanding and improved confidence in
their caregiving abilities at 6 months (ps > 0.05). However, TAP caregivers compared to attention control
group caregivers were more likely to report that participation made life easier (86.1 % vs. 75.0 %, p = 0.052), enhanced ability to provide care (97.0 % vs. 85.4 %, p =
0.004) and improved PLWD’s life (80.4 % vs. 67.4 %, p =
0.048) somewhat or very much.

Discussion
We conducted a randomized controlled trial to examine
the effectiveness of tailoring activities on agitation/

Table 3 Comparison of TAP and Attention Control on Health-related Events: Number of Persons and Events
Category of Event

Total

TAP (N = 124)

Attention Control (N =
126)

# Persons # Events # Persons # Events # Persons

p-values = # of persons

# Events

Unadjustedp-value Adjusted
p-value*

Person living with dementia
Death

11

11

4

4

7

7

0.37

0.38

Health related

43

54

15

18

28

36

0.04

0.03

Hospitalization

34

42

10

13

24

29

Emergency room

9

10

5

5

4

5

Depression or
suicidal ideation
(Proxy report)

2

2

0

0

2

2

13

15

3

4

10

11

0.06

0.07

Elevated depression and/or suicidal ideation 30

35

16

19

14

16

0.66

0.78

Caregiver
Hospitalizations

Note: Bold signifies significant p value < 0.05; *Adjusted for caregiver race, gender, education, relationship with person living with dementia, baseline Mini-mental
Status Examination (MMSE)
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aggression as well as on other outcomes that matter to
PLWD and caregivers. Contrary to our hypothesis, TAP
did not improve agitation/aggression, the main study
outcome at 3 months. However, compared to an attention control, in this sample with clinically significant
dementia-related agitation/aggression, TAP benefits
were evident for PLWD functional dependence, as well
as caregiver well-being and confidence in using activity,
with less assistance and improved wellbeing and confidence favoring TAP dyads. Benefits for caregivers approximated small to medium standardized treatment
effect sizes. Importantly, TAP caregivers tended to report fewer health-related events over six months for
PLWD, including deaths and hospitalizations. Also, a
trend was found for TAP caregivers to report fewer hospitalizations for themselves compared to controls. These
outcomes may result in cost savings which should be a
future analytic focus.
Specifically, as it concerns NPS, the main trial outcome, the null treatment effect of TAP was disappointing. This finding is in contrast to other randomized
trials of TAP which have shown improvements in a
range of behavioral symptoms including agitation [14,
15, 19, 20, 34]. This positive impact of TAP on behavioral symptoms has been reported in trials conducted in
the United States [14, 15], Brazil [19, 34], and Australia
[20]. The null finding in this trial may be due to several
reasons. First, this trial included a sample of PLWD that
was determined by a medical team to verify a dementia
diagnosis and presence of clinically significant/agitation/
aggression. This provided a level of rigor not achieved in
other trials resulting in a sample in which all PLWDs
had a baseline level of clinically meaningful agitation/aggression-type behaviors. Second, this is the first trial that
compared TAP to an attention control group that provided empathy and attention in addition to disease education and home safety tips. The group appeared to be
meaningful to caregivers and appeared to have addressed
an unmet need for disease education.
Agitation and aggression are among the most complex,
problematic and treatment resistant dementia-related
symptoms. Under this trial’s test circumstances and for
this study sample, there was no impact on these behaviors. Nevertheless, it is possible that some subgroups
benefited more than others in this area. Given that other
trials have shown behavioral symptom reductions, future
analyses are warranted with this same study sample to
determine if there were differential treatment effects by
gender, relationship or race. Also, future trials with better characterized patient samples should examine TAP
effects by disease etiology and disease stage.
As to functional dependence, TAP instructed caregivers in specific approaches to support activity participation of PLWD including ways to set up the prescribed
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activities, how to cue and use other communication
strategies, and modify the environment to facilitate engagement. Caregivers were also instructed in how to use
effective practices to manage basic and instrumental activities of daily living and practiced their use in the presence of the occupational therapist and then
independently. Use of strategies may have positively affected functional status by decreasing excess disability or
dependence over and above underlying impairments. Although the difference in the number of IADLs and ADLs
for which assistance was needed was small between TAP
and control groups at 3 months, this difference was significant and also consistent with findings from other
TAP trials [15]. The adjusted mean differences of 0.33
and 0.59, respectively, although small, may be clinically
significant. It suggests that caregiver assistance was not
needed for close to one less daily instrumental/self-care
activity. As other studies have shown that increased
functional dependence is a predictor of more hours caregiving, hospitalizations and nursing home placements
[35], even a small decline in the rate of dependence over
time may lessen caregiver burden and improve PLWD
quality of life. Trials in Brazil found that TAP resulted in
significant quality of life improvements of PLWD as perceived by persons themselves and by their caregivers,
and also caregivers perceived quality of life improvements for themselves [19, 34].
The other important finding from this trial was that
compared to control group dyads, TAP dyads demonstrated significant health-related improvements: there
was a 48.8 % improvement in health-related events for
PLWD and a 63.6 % improvement in caregiver hospitalizations in TAP versus controls. The difference in the
number of PLWD with hospitalizations in TAP versus
control was statistically significant (p = 0.03). We did not
find however, statistically significant differences in the
number of caregivers with major or severe depression
[45]. The total number of caregivers by 6 months with
elevated scores was a small percentage (0.12 %) of the
sample and no large or statistically significant change
was observed following treatment in either arm for this
subgroup. This suggests that caregivers with clinical depression and/or suicidal ideation need more direct
depression-focused interventions to improve on this outcome. This is in contrast to a Brazilian trial which found
significant differences such that caregivers in TAP compared to those in usual care had improved quality of life,
and decreased depression and burden scores [19].
To our knowledge, there is no other TAP trial that has
examined health-related events with one exception. A
trial of 160 Veterans found that TAP caregivers compared to those in usual care, reported significantly less
pain in PLWD following intervention [15]. That study
and the present trial suggest that tailored activities may
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have far reaching health benefits including reducing incidents of hospitalizations for both PLWD and caregivers
that should be further examined in future research studies on TAP and that reduced incidents may result as well
in cost savings.
Significantly, caregivers reported that prescribed TAP
activities were well tolerated by PLWD with < 5 % demonstrating anxiety and < 3 % agitation “very much” when
used at home between treatment sessions. As some, although very few, PLWD were observed as agitated or
anxious when engaging in prescribed activities, careful
oversight and monitoring appear to be important to address and mitigate PLWD distress if it should occur.
TAP is a therapeutic modality and thus, necessitates
monitoring.
A critical question remains as to the mechanism by
which tailoring activities achieves its positive effects. The
data from this trial and others strongly suggests that different mechanisms should be examined to fully understand the pathways by which engaging in tailored
activities effects behaviors, function, and other aspects of
wellbeing. It may be that tailoring activities to interests
and abilities help PLWD remain physically, socially, and
psychologically engaged and derive a sense of meaning
and purpose. Purpose is an enduring need regardless of
disease stage and etiology [36]. There may also be a
neurobiological link that should be explored. Remaining
engaged in an activity may help people remain physically
active, reduce pain, reduce physiological stress and positively affect circadian rhythms [15, 37, 38].
A few study limitations should be noted. First, caregivers who volunteer for a clinical trial may differ in important ways from those who do not volunteer [39].
Enrolled caregivers may be more ready to try new management strategies, such as activities, may have more
time to set up and use activities, and may not be as burdened as those who do not volunteer. TAP requires active involvement of caregivers and thus, it is not
unexpected that at baseline, those who did not complete
the study reported a poorer relationship with PLWD,
and lower cognitive status and poorer quality of life of
PLWD compared to those who stayed in the study. Second, the measurement of behavioral and psychological
symptoms is dependent upon caregiver recall. It is unclear as to the relationship between a caregiver’s mental
health and their ratings of behavioral occurrences with
some evidence suggesting that depressed caregivers report more behaviors than their counterparts [40]. Caregivers with higher depression and expressed burden may
perceive behavioral symptoms as occurring more frequently or severely, but this relationship needs further
investigation. Furthermore, some behavioral symptoms
may impact caregiver wellbeing more so than others and
thus effects their reporting of frequency and severity.
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There is some evidence to suggest that the number of
behaviors being managed versus behavior-type and perceived stress are associated with caregiver burden and
depression [41–43]. The evidence is inconclusive and associational, lacking hypothesis-driven analyses or testing
of causal mechanisms. While measurement of behaviors
symptoms and overreliance on family reports remains a
critical issue, we did use the NPI-C which is widely used
internationally and shown to be a reliable and valid
measure. While caregivers reported behavioral symptoms (versus clinicians), interviewers were trained to explain each behavior using the administration guidelines
for the NPI-C. Also, the NPI-C has detailed behaviors
for each of its domains, making it the preferred tool in
trials such as TAP.
Another limitation may concern disease staging. While
we obtained and reported on the cognitive status of
PLWD, we were unable to identify etiology and disease
stage, a common issue in nonpharmacological trials. Although understanding the role of activity for different
disease stages and etiologies may be an avenue for future
research, TAP is designed to address and mitigate the
functional consequences of any of dementia-type or disease stage. Its tailoring function seeks to assure the “just
right fit” between capabilities of PLWD and an activity.
Most caregivers overestimate abilities of the person for
whom they care [44]. TAP seeks to adjust caregiver
communications and the environment and grade activities to match PLWD preserved abilities. That is, TAP
seeks to provide a supportive environment such that
PLWD is able to function at their best at each disease
stage.
Finally, while not a limitation, we did find that contact
time differed between the two treatment arms. Future
research will need to examine the relationship of contact
time on outcomes and dose-response relationships.
Improving quality of life of PLWD is an important
treatment goal. Engagement in meaningful activity is an
essential and enduring need and caregiver and PLWD
report lack of activity engagement as a major concern.
Based on the findings from this and other trials, TAP
should be considered as a therapeutic approach in dementia care. By enabling engagement in meaningful activities that are structured to match abilities, we show
that TAP improves important aspects of quality of life of
PLWD. Importantly, TAP improved caregiver wellbeing
and reduced caregiver and PLWD health-related events.
This study contributes to the growing body of literature suggesting that individualized activity approaches
may address a wide range of clinical symptoms although
agitation and aggressive behaviors alluded improvement
for this particular study sample. Future research needs
to examine program costs, whether caregivers continue
to use activities over time and if so, the long-term
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effects, whether certain dyads benefit more than others,
and the underlying mechanisms by which its impacts are
achieved.
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